Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents
© 2022. The Author(s)..
We present an interim analysis of a registered clinical study (NCT04800133) to establish immunobridging with various antibody and cellular immunity markers and to compare the immunogenicity and reactogenicity of 2-dose BNT162b2 and CoronaVac in healthy adolescents as primary objectives. One-dose BNT162b2, recommended in some localities for risk reduction of myocarditis, is also assessed. Antibodies and T cell immune responses are non-inferior or similar in adolescents receiving 2 doses of BNT162b2 (BB, N = 116) and CoronaVac (CC, N = 123) versus adults after 2 doses of the same vaccine (BB, N = 147; CC, N = 141) but not in adolescents after 1-dose BNT162b2 (B, N = 116). CC induces SARS-CoV-2 N and N C-terminal domain seropositivity in a higher proportion of adolescents than adults. Adverse reactions are mostly mild for both vaccines and more frequent for BNT162b2. We find higher S, neutralising, avidity and Fc receptor-binding antibody responses in adolescents receiving BB than CC, and a similar induction of strong S-specific T cells by the 2 vaccines, in addition to N- and M-specific T cells induced by CoronaVac but not BNT162b2, possibly implying differential durability and cross-variant protection by BNT162b2 and CoronaVac, the 2 most used SARS-CoV-2 vaccines worldwide. Our results support the use of both vaccines in adolescents.
| Errataetall: |
ErratumIn: Nat Commun. 2022 Aug 15;13(1):4798. - PMID 35970832 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Nature communications - 13(2022), 1 vom: 28. Juni, Seite 3700 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rosa Duque, Jaime S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BNT162 Vaccine |
|---|
| Anmerkungen: |
Date Completed 30.06.2022 Date Revised 23.10.2022 published: Electronic ClinicalTrials.gov: NCT04800133 ErratumIn: Nat Commun. 2022 Aug 15;13(1):4798. - PMID 35970832 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41467-022-31485-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM342855492 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM342855492 | ||
| 003 | DE-627 | ||
| 005 | 20231226015058.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41467-022-31485-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1142.xml |
| 035 | |a (DE-627)NLM342855492 | ||
| 035 | |a (NLM)35764637 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rosa Duque, Jaime S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.06.2022 | ||
| 500 | |a Date Revised 23.10.2022 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04800133 | ||
| 500 | |a ErratumIn: Nat Commun. 2022 Aug 15;13(1):4798. - PMID 35970832 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a We present an interim analysis of a registered clinical study (NCT04800133) to establish immunobridging with various antibody and cellular immunity markers and to compare the immunogenicity and reactogenicity of 2-dose BNT162b2 and CoronaVac in healthy adolescents as primary objectives. One-dose BNT162b2, recommended in some localities for risk reduction of myocarditis, is also assessed. Antibodies and T cell immune responses are non-inferior or similar in adolescents receiving 2 doses of BNT162b2 (BB, N = 116) and CoronaVac (CC, N = 123) versus adults after 2 doses of the same vaccine (BB, N = 147; CC, N = 141) but not in adolescents after 1-dose BNT162b2 (B, N = 116). CC induces SARS-CoV-2 N and N C-terminal domain seropositivity in a higher proportion of adolescents than adults. Adverse reactions are mostly mild for both vaccines and more frequent for BNT162b2. We find higher S, neutralising, avidity and Fc receptor-binding antibody responses in adolescents receiving BB than CC, and a similar induction of strong S-specific T cells by the 2 vaccines, in addition to N- and M-specific T cells induced by CoronaVac but not BNT162b2, possibly implying differential durability and cross-variant protection by BNT162b2 and CoronaVac, the 2 most used SARS-CoV-2 vaccines worldwide. Our results support the use of both vaccines in adolescents | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Wang, Xiwei |e verfasserin |4 aut | |
| 700 | 1 | |a Leung, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Samuel M S |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Carolyn A |e verfasserin |4 aut | |
| 700 | 1 | |a Mu, Xiaofeng |e verfasserin |4 aut | |
| 700 | 1 | |a Hachim, Asmaa |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yanmei |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Sau Man |e verfasserin |4 aut | |
| 700 | 1 | |a Chaothai, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Kwan, Kelvin K H |e verfasserin |4 aut | |
| 700 | 1 | |a Chan, Karl C K |e verfasserin |4 aut | |
| 700 | 1 | |a Li, John K C |e verfasserin |4 aut | |
| 700 | 1 | |a Luk, Leo L H |e verfasserin |4 aut | |
| 700 | 1 | |a Tsang, Leo C H |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Wilfred H S |e verfasserin |4 aut | |
| 700 | 1 | |a Cheang, Cheuk Hei |e verfasserin |4 aut | |
| 700 | 1 | |a Hung, Timothy K |e verfasserin |4 aut | |
| 700 | 1 | |a Lam, Jennifer H Y |e verfasserin |4 aut | |
| 700 | 1 | |a Chua, Gilbert T |e verfasserin |4 aut | |
| 700 | 1 | |a Tso, Winnie W Y |e verfasserin |4 aut | |
| 700 | 1 | |a Ip, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Mori, Masashi |e verfasserin |4 aut | |
| 700 | 1 | |a Kavian, Niloufar |e verfasserin |4 aut | |
| 700 | 1 | |a Leung, Wing Hang |e verfasserin |4 aut | |
| 700 | 1 | |a Valkenburg, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Peiris, Malik |e verfasserin |4 aut | |
| 700 | 1 | |a Tu, Wenwei |e verfasserin |4 aut | |
| 700 | 1 | |a Lau, Yu Lung |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature communications |d 2010 |g 13(2022), 1 vom: 28. Juni, Seite 3700 |w (DE-627)NLM199274525 |x 2041-1723 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2022 |g number:1 |g day:28 |g month:06 |g pages:3700 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41467-022-31485-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2022 |e 1 |b 28 |c 06 |h 3700 | ||